Exom today launched the industry’s first ever conducted Cloud & Mobile Clinical Trial , Caravaggio, that involves about 160 clinical sites across Europe, Israel and USA.
The digital backbone of the Caravaggio Study, is Genius SUITE®, the first multitenant cloud and mobile application that unifies information, documentation, data and processes globally for a single sign-on access and source of truth across any clinical trial. With Genius SUITE® both study’s sponsors and investigators can accelerate trial execution and gain real-time visibility into any trial related operations.
“The conduction and oversight of a clinical trial is an highly complex and often inefficient ecosystem due to a number of factors, including the inconsistent use of a large number of disparate and incompatible technologies” – said Luigi Visani, President & CEO of Exom Group, The Digital and Human CRO, headquartered in Milano (Italy) – “Real-time and mobile access, compatibility, integration and completeness are critical factors driving technology solutions adoption among clinical research professionals and patients. Exom Group is bringing the next generation of clinical trial to the clinical research stakeholders. We are revolutionizing the CRO industry with the unique combination of human professional skills and services with a unified suite of applications to provide one process, one system, and one view within and across clinical trials , while reducing costs and increasing quality and performance “.